Skip to main content

Table 1 Baseline characteristics of children with juvenile idiopathic arthritis treated with etanercepta

From: Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

  All patients
(n = 1038)
Cross-sectional groupb
(n = 422)
Retrospective groupc
(n = 616)
P
Female 781 (75.2) 335 (79.4) 446 (72.4) 0.01
ILAR category
 Systemic arthritis 106 (10.2) 21 (5) 85 (13.8) <0.0001
 Persistent oligoarthritis 139 (13.4) 60 (14.2) 79 (12.8) 0.52
 Extended oligoarthritis 325 (31.3) 147 (34.8) 178 (28.9) 0.04
 RF-negative polyarthritis 329 (31.7) 138 (32.7) 191 (31) 0.56
 RF-positive polyarthritis 50 (4.8) 16 (3.8) 34 (5.5) 0.20
 Enthesitis-related arthritis 48 (4.6) 21 (5) 27 (4.4) 0.65
 Psoriatic arthritis 34 (3.3) 16 (3.8) 18 (2.9) 0.44
 Undifferentiated arthritis 7 (0.7) 3 (0.7) 4 (0.6) 1.0
Patients with positive ANA 586/1028 (57) 278 (66.5) 308 (50.5) <0.0001
Median (IQR) age at disease onset, years 4.1 (2–8.3) 3.5 (1.8–7.3) 4.7 (2.1–9.1) 0.001
Median (IQR) age, years 10.1 (6.2–13.9) 9.6 (5.8–13.6) 10.4 (6.9–14.2) 0.04
Median (IQR) disease duration, years 3.5 (1.3–7.5) 3.6 (1.4–7.8) 3.3 (1.3–7.3) 0.16
Patients aged < 4 years 122 (11.8) 54 (12.8) 68 (11) 0.39
Median (IQR) follow-up durationd, years 2.1 (0.6–5.5) 2.4 (0.7–6.3) 2.1 (0.5–5.1) 0.04
Treatments before ETN start
 NSAIDs 603 (58.1) 269 (63.7) 334 (54.2) 0.002
 Systemic corticosteroids 527 (50.8) 198 (46.9) 329 (53.4) 0.04
 Intra-articular corticosteroids 579 (55.8) 263 (62.3) 316 (51.3) 0.0004
 Methotrexate 930 (89.6) 387 (91.7) 543 (88.1) 0.07
 Other synthetic DMARDs 187 (18) 48 (11.4) 139 (22.6) <0.0001
 Other biologic agents 53 (5.1) 18 (4.3) 35 (5.7) 0.31
Concomitant therapies during ETN administration
 Systemic corticosteroids 267 (25.7) 93 (22) 174 (28.2) 0.02
 Intra-articular corticosteroids 257 (24.8) 98 (23.2) 159 (25.8) 0.34
 Methotrexate 749 (72.2) 311 (73.7) 438 (71.1) 0.36
 Other synthetic DMARDs 73 (7) 17 (4) 56 (9.1) 0.002
  1. ILAR International League of Associations for Rheumatology, ANA antinuclear antibodies, ETN etanercept, IQR interquartile range, NSAIDs nonsteroidal anti-inflammatory drugs, DMARDs disease-modifying antirheumatic drugs
  2. aData are number (percentage) unless otherwise indicated
  3. bIncludes patients still receiving ETN
  4. cIncludes patients discontinued from ETN or lost to follow-up
  5. dDuration of follow-up at study center